Skip to main content

Table 1 Clinical and morphological characteristics of patients with or without chemo-resistance

From: Clinical analysis of chemo-resistance risk factors in endometriosis associated ovarian cancer

Variable Category Number(%) Chemo-sensitive(%) Chemoresistance(%) P
   304 252(82.9%) 52(17.1%)  
Age < 48 129(42.43) 114(45.24) 15(28.85) 0.0294*
≥48 175(57.57) 138(54.76) 37(71.15)  
Menopausal status Pre 161(52.96) 139(55.16) 22(42.31) 0.0909
Post 143(47.04) 113(44.84) 30(57.69)  
Gravidity < 1 35(11.51) 31(12.3) 4(7.69) 0.3431
> = 1 269(88.49) 221(87.7) 48(92.31)  
Parity < 1 51(16.78) 46(18.25) 5(9.62) 0.1290
> = 1 253(83.22) 206(81.75) 47(90.38)  
Abdominal pain No 210(69.08) 174(69.05) 36(69.23) 0.9016
Yes 93(30.59) 77(30.56) 16(30.77)  
Bloating No 243(79.93) 208(82.54) 35(67.31) 0.0125*
Yes 61(20.07) 44(17.46) 17(32.69)  
Palpable mass No 223(73.36) 182(72.22) 41(78.85) 0.3253
Yes 81(26.64) 70(27.78) 11(21.15)  
Incidental finding No 256(84.21) 208(82.54) 48(92.31) 0.0786
Yes 48(15.79) 44(17.46) 4(7.69)  
Irregular menstruation No 275(90.46) 226(89.68) 49(94.23) 0.3094
Yes 29(9.54) 26(10.32) 3(5.77)  
Postmenopausal bleeding No 285(93.75) 235(93.25) 50(96.15) 0.4316
Yes 19(6.25) 17(6.75) 2(3.85)  
Emaciation No 294(96.71) 248(98.41) 46(88.46) 0.0002*
Yes 10(3.29) 4(1.59) 6(11.54)  
Abnormal vaginal discharge No 302(99.34) 250(99.21) 52(100) 0.5192
Yes 2(0.66) 2(0.79) 0(0)  
Ca125 in normal range(< 35 U/L) No 249(81.91) 199(78.97) 50(96.15) 0.0034*
Yes 55(18.09) 53(21.03) 2(3.85)  
CA125group < 90 112(36.84) 104(41.27) 8(15.38) 0.0004*
≥90 192(63.16) 148(58.73) 44(84.62)  
Early or late Stage FIGO I + II 185(60.86) 175(69.44) 10(19.23) <.0001*
FIGO III + IV 119(39.14) 77(30.56) 42(80.77)  
FIGO stagea I 141(46.38) 136(53.97) 5(9.62) <.0001*
II 44(14.47) 39(15.48) 5(9.62)  
III 104(34.21) 69(27.38) 35(67.31)  
IV 15(4.93) 8(3.17) 7(13.46)  
Tumor size group < 7 80(26.32) 66(26.19) 14(26.92) 0.9130
≥7 224(73.68) 186(73.81) 38(73.08)  
Pathology Grade G1 45(24.19) 44(28.03) 1(3.45) 0.0128*
G2 59(31.72) 49(31.21) 10(34.48)  
G3 82(44.09) 64(40.76) 18(62.07)  
Pathology type Endometrioid 186(61.18) 157(62.30) 29(55.77) 0.435
Clear cell 118(38.82) 95(37.70) 23(44.23)  
Endometriosis No 235(77.30) 188(74.6) 47(90.38) 0.0134*
Yes 69(22.70) 64(25.4) 5(9.62)  
Side of tumor Unilateral 212(69.74) 183(72.62) 29(55.77) 0.0160*
Bilateral 92(30.26) 69(27.38) 23(44.23)  
LN metastasis No 213(70.07) 195(77.38) 18(34.62) <.0001*
Yes 40(13.16) 24(9.52) 16(30.77)  
unclear 51(16.78) 33(13.1) 18(34.62)  
LN dissection No 51(16.78) 33(13.1) 18(34.62) 0.0002*
Yes 253(83.22) 219(86.9) 34(65.38)  
Residual disease No 231(75.99) 207(82.14) 24(46.15) <.0001*
Yes 73(24.01) 45(17.86) 28(53.85)  
TH No 297(97.7) 246(97.62) 51(98.08) 0.8411
Yes 7(2.3) 6(2.38) 1(1.92)  
Tubal ligation No 290(95.39) 243(96.43) 47(90.38) 0.0583
Yes 14(4.61) 9(3.57) 5(9.62)  
Sterilization surgery No 283(93.09) 237(94.05) 46(88.46) 0.1481
Yes 21(6.91) 15(5.95) 6(11.54)  
Endometrial disorder No 252(82.89) 208(82.54) 44(84.62) 0.7174
Yes 52(17.11) 44(17.46) 8(15.38)  
Variable endometrial disorder No 252(82.89) 207(82.14) 45(86.54) 0.7998
EP 27(8.88) 23(9.13) 4(7.69)  
EIN 22(7.24) 19(7.54) 3(5.77)  
EC 3(0.99) 3(1.19) 0(0)  
Breast cancer No 296(97.37) 248(98.41) 48(92.31) 0.0123*
Yes 8(2.63) 4(1.59) 4(7.69)  
HT No 250(82.24) 208(82.54) 42(80.77) 0.7610
Yes 54(17.76) 44(17.46) 10(19.23)  
DM No 286(94.08) 236(93.65) 50(96.15) 0.4862
Yes 18(5.92) 16(6.35) 2(3.85)  
  1. aAccording to the classification system of FIGO staging (2013 version)
  2. Abbreviation: Ca125 cancer antigen 125, EM endometriosis, LN lymph node, TH total hysterectomy, EP endometrial polyps, EIN endometrial intraepithelial neoplasm, EC endometrial cancer, HT hypertension, DM diabetic mellitus
  3. *P < 0.05